Spring 2005 Volume 6, Issue 4
Program Highlights from the 10th International Workshop in Myeloma
IMFers Share Their Thoughts
Patient Perspective: Tracking My Numbers
My MGUS was found as a fluke during an annual physical in May, 1993. My total serum protein was slightly above the top of the normal range for that test and soon went back to normal. Otherwise, I still would not know that I have MGUS since I am still
Patient Perspective: My New First Birthday
Update on Lenalidomide (CC-5013; Revlimid®)
There has been intense research to develop a safer and more effective version of thalidomide. Lenalidomide (CC-5013; Revlimid®) is the first analog (close cousin) of thalidomide to enter clinical trials. It may prove to be more effective and safe
Meet New Members of the IMF Scientific Advisory Board
Supportive Care: Erectile Dysfunction - Current Treatment Options
Erectile dysfunction (ED) is a very common disorder that affects up to half the male population over the age of 40.
IMF Hotline Coordinators Answer Your Questions
What is the difference between the terms "myeloma" and "multiple myeloma?" "My grandmother died of multiple myeloma and now my dad has been diagnosed with this disease. Is myeloma hereditary?"
Supportive Care: Blood Tests
There are a number of factors that are likely to increase your comfort with a medical test. Susan J. Leclair, PhD, CLS (NCA)helps you understand why a test has been ordered for you, how it will be conducted, and what the reference ranges are.
Dallas Patient & Family Seminar
Community Goals Lead to Results
Are you more interested in myeloma research or cancer research? Is there a difference? What about other issues, like drug coverage and payments for PET scans? Can myeloma issues be separated from cancer issues in general?
IMF Receives Highest Four-Star Rating
Sorority Raises Funds for a Cure
During the summer of 2004, my father was diagnosed with multiple myeloma. Myeloma? I had never heard of this disease. And I was not alone.
Myeloma Foundation of Australia Inc.
2005 Brian D. Novis Research Grants
Did You Know: What Causes Hyperviscosity in Multiple Myeloma?
Viscosity is the property of fluid to resist flow. In myeloma patients, hyperviscosity (increased serum viscosity) results from increased levels of circulating serum immunoglobulins.